Therefore, LXNX formula’s mechanism of treating CHD and co-morbid diseases and symptoms could be as such: LXNX formula acts upon CRH, and then influences the HPA axis through GPCRs signaling transduction pathway related to CRHR1 and POMC. This evidence concerns the gene POMC and coronary artery disorder.